Barinthus Biotherapeutics plc (BRNS): Valuation
TTM figures as of June 30, 2026
Barinthus Biotherapeutics plc trades at a -87.42% free-cash-flow yield. That FCF yield is higher than 26% of its own month-end history back to 2021.
Earnings yield -138.17%.
65 month-end valuation observations are on file, starting April 2021.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is BRNS cheap versus its own history?
Barinthus Biotherapeutics plc trades at a -87.42% free-cash-flow yield. That FCF yield is higher than 26% of its own month-end history back to 2021.
What is BRNS's free-cash-flow yield?
Barinthus Biotherapeutics plc currently yields -87.42% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.